PATENT CLAIM ANALYSIS

Application Number: 16076479
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["424", "136100"]

Abstract:
The present invention relates to engineered cells, engineered chimaeric antigen ligands (CALs), novel uses of multi-specific binding agents for bridging cells, and methods of therapy. The invention also provides variation-matched engineered cells.

Claim (Index 87):
The method of  claim 83 , wherein the bridging agent\n (a) is a bi- or tri-specific antigen binding fragment comprising two or three scFv binding sites respectively; or (b) is or comprises a bispecific T-cell engager antibody, bispecific-scFv, trispecific scFv, tandab, dAb, nanobody multimer, nanobody dimer, nanobody timer, dAb multimer, dAb dimer, dAb trimer, diabody, triabody, tetrabody or Dual-affinity Re-targeting Antibody (DART).

Metadata:
- Claim Count in Document: 53.0
- Percentile: 96.0
- Lexical Diversity: 1.34483
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15866222', '15934770', '15105074', '15637734', '15106783']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7388932105102736
- 35 USC 102 Novelty (BERT): 0.5204538195259022
- Combined Prediction Score: 0.7170492714118365
- Mean Citation Score: 319.32395
- Max Citation Score: 322.89294
- Similarity Product: 219.4812299893856

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test